New pill for fatty liver disease enters first human tests

NCT ID NCT06485245

Ongoing Disease control Sponsor: Cascade Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called CS060304 in healthy volunteers and people with high LDL-C (bad cholesterol), a risk factor for MASH (a serious liver disease). The main goal is to check if the drug is safe and how the body processes it. 80 participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS060304 (a tablet taken by mouth)
What this could lead to: If successful, this could lead to a new treatment option for MASH, a liver disease with few approved therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (80 people) and may not show any benefit or could reveal unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASH

Contacts and locations

Show contact details

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.